Q4 2024 · 13F-HR
ARCH Venture Management, LLCholdings as filed
Filed 2025-02-14 · accession 0001012975-25-000089
$230.2M
Reported value
9
Positions
2024-12-31
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 07373V105 | BEAM | BEAM THERAPEUTICS INC. | $112.6M | 48.9% | 4,540,132 | Common | NONE |
| 75383L102 | RAPP | RAPPORT THERAPEUTICS, INC. | $66.1M | 28.7% | 3,728,738 | Common | NONE |
| 29479A108 | ERAS | ERASCA, INC. | $27.7M | 12.1% | 11,055,554 | Common | NONE |
| 92539P101 | — | VERVE THERAPEUTICS, INC. | $11.3M | 4.92% | 2,008,809 | Common | NONE |
| 38341P102 | GOSS | GOSSAMER BIO, INC. | $7.3M | 3.17% | 8,055,916 | Common | NONE |
| 82933R308 | — | SINGULAR GENOMICS SYSTEMS, INC. | $2.5M | 1.07% | 126,630 | Common | NONE |
| 746964105 | QTTB | Q32 BIO INC. | $1.1M | 0.48% | 320,482 | Common | NONE |
| 91381U200 | UNBX | UNITY BIOTECHNOLOGY, INC. | $981,103 | 0.43% | 1,004,817 | Common | NONE |
| 71902K105 | — | CERO THERAPEUTICS HOLDINGS, INC. | $563,614 | 0.24% | 9,393,561 | Common | NONE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.